Repository logo
  • English
  • Srpski (lat)
  • Српски
Log In
Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "Fuhrmann, Tarek (57196246307)"

Filter results by typing the first few letters
Now showing 1 - 1 of 1
  • Results Per Page
  • Sort Options
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Multicenter prospective study on multivariant diagnostics of autoimmune bullous dermatoses using the BIOCHIP technology
    (2020)
    van Beek, Nina (24529335200)
    ;
    Krüger, Stine (57196235041)
    ;
    Fuhrmann, Tarek (57196246307)
    ;
    Lemcke, Susanne (35074384800)
    ;
    Goletz, Stephanie (56116153500)
    ;
    Probst, Christian (24172548400)
    ;
    Komorowski, Lars (23389479400)
    ;
    Di Zenzo, Giovanni (15759309300)
    ;
    Dmochowski, Marian (6602554858)
    ;
    Drenovska, Kossara (8747665300)
    ;
    Horn, Michael (7202765812)
    ;
    Jedlickova, Hana (22937832000)
    ;
    Kowalewski, Cezary (6603993342)
    ;
    Medenica, Ljiljana (16744100000)
    ;
    Murrell, Dedee (7005224296)
    ;
    Patsatsi, Aikaterini (22635846900)
    ;
    Geller, Shamir (55827543300)
    ;
    Uzun, Soner (7004162780)
    ;
    Vassileva, Snejina (7003473922)
    ;
    Zhu, Xuejun (57215579084)
    ;
    Fechner, Kai (28767622100)
    ;
    Zillikens, Detlef (7005214133)
    ;
    Stöcker, Winfried (57219637594)
    ;
    Schmidt, Enno (35501678400)
    ;
    Rentzsch, Kristin (55251967400)
    Background: The current standard in the serologic diagnosis of autoimmune bullous diseases (AIBD) is a multistep procedure sequentially applying different assays. In contrast, the BIOCHIP Mosaic technology combines multiple substrates for parallel analysis by indirect immunofluorescence. Methods: Sera from 749 consecutive, prospectively recruited patients with direct immunofluorescence–positive AIBD from 13 international study centers were analyzed independently and blinded by using (1) a BIOCHIP Mosaic including primate esophagus, salt-split skin, rat bladder, monkey liver, monkey liver with serosa, recombinant BP180 NC16A, and gliadin GAF3X, as well as HEK293 cells expressing recombinant desmoglein 1, desmoglein 3, type VII collagen, and BP230 C-terminus and (2) the conventional multistep approach of the Department of Dermatology, University of Lübeck. Results: In 731 of 749 sera (97.6%), specific autoantibodies could be detected with the BIOCHIP Mosaic, similar to the conventional procedure (725 cases, 96.8%). The Cohen κ for both serologic approaches ranged from 0.84 to 1.00. In 6.5% of sera, differences between the 2 approaches occurred and were mainly attributed to autoantigen fragments not present on the BIOCHIP Mosaic. Limitations: Laminin 332 and laminin γ1 are not represented on the BIOCHIP Mosaic. Conclusions: The BIOCHIP Mosaic is a standardized time- and serum-saving approach that further facilitates the serologic diagnosis of AIBD. © 2020 American Academy of Dermatology, Inc.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Privacy policy
  • End User Agreement
  • Send Feedback